MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • MDS Virtual Congress 2021

    LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Protocol and feasibility study

    T. Usnich, EJ. Vollstedt, N. Schell, V. Skrahina, X. Bogdanovic, H. Gaber, T. Förster, A. Heuer, N. Koleva-Alazeh, I. Csoti, A. Nazli Basak, S. Ertan, G. Genc, P. Bauer, K. Lohmann, A. Grünewald, E. Schymanski, J. Trinh, S. Schaake, D. Berg, D. Gruber, S. Isaacson, A. Kühn, B. Mollenhauer, D. Pedrosa, K. Reetz, E. Sammler, EM. Valente, F. Valzania, J. Volkmann, S. Zittel, N. Brüggemann, M. Kasten, A. Rolfs, C. Klein (Lübeck, Germany)

    Objective: To systematically assess clinical signs and symptoms including non-motor features, comorbidities, medication and environmental factors in 1,000 participants internationally: 300 with LRRK2 (Leucine-rich repeat…
  • MDS Virtual Congress 2021

    Correlating LRRK2 activation status in peripheral blood to urine BMPs in monogenic and idiopathic Parkinson’s disease

    S. Gomes, A. Garrido, F. Tonelli, E. Tolosa, M. Marti, D. Anderson, N. Pratuseviciute, F. Hsieh, T. Bruecke, T. Koenig, C. Hotzy, J. Ruiz-Martínez, A. Bergareche-Yarza, E. Mondragón Rezola, A. Vinagre Aragón, I. Croitoru, A. Gorostidi Pagola, L. Paternain Markinez, F. Valldeoriola, K. Merchant, S. Padmanabhan, A. Zimprich, D. Alessi, E. Sammler (Dundee, United Kingdom)

    Objective: The greatest unmet need in Parkinson’s disease (PD) are disease-modifying treatments. The discovery of monogenic forms of PD has provided invaluable insights into pathomechanisms…
  • MDS Virtual Congress 2020

    First clinical and genetic analysis of LRRK2 G2019S, R1441G/C/H/, I2020T and Y1699C mutations in Costa Rican patients with Parkinson’s disease

    A. Hernandez-Guillen, T. Lobo-Prada, J. Ruiz-Martinez, A. Gorostidi-Pagola, Z. Gan-Or, K. Carazo-Cespedes, J. Fornaguera-Trias, G. Torrealba-Acosta (San José, Costa Rica)

    Objective: To assess the frequency of G2019S, R1441G/C/H, I2020T and Y1699C mutations in a Costa Rican cohort of Parkinson’s disease (PD) cases and controls. Background:…
  • MDS Virtual Congress 2020

    Virtual Assessment of LRRK2 Carriers to Optimize Research in Parkinson Disease (VALOR-PD): A Comparison to Traditional Cohorts

    S. Jensen-Roberts, T. Myers, K. Amodeo, S. Sharma, R. Alcalay, E. Dorsey, R. Holloway, R. Schneider (Rochester, NY, USA)

    Objective: To compare a national virtual cohort of LRRK2 G2019S carriers, identified via a personal genetics company, to existing traditional cohorts. Background: Advancements in personal…
  • MDS Virtual Congress 2020

    Rare variants of the LRRK2 gene in the haplotype as one of the potential risk factors for endemic parkinsonism in a small isolated region in the Czech Republic

    P. Kaňovský, K. Kolaříková, R. Vodička, R. Vrtěl, K. Menšíková, T. Bartoníková, M. Procházka (Olomouc, Czech Republic)

    Objective: The aim of the study was to investigate a co-occurence of rare variants in set of genes frequently associated with parkinsonism. Background: The increased…
  • MDS Virtual Congress 2020

    Interest of multiplex ligation-dependent probe amplification assay to identify pathogenic mutations in Parkinson’s disease patients

    E. Mutez, M. Swiderski, L. Defebvre, M.C Chartier-Harlin, V. Huin (Lille, France)

    Objective: To evaluate the interest of the MLPA (Multiplex Ligation-dependent Probe Amplification) commercially available kit in the genetic testing in Parkinson’s disease (PD). Background: PD…
  • MDS Virtual Congress 2020

    LRRK2 p.G2019S and p.N2081D variants as modifiers of glucocerebrosidase activity

    K. Senkevich, E. Yu, L. Krohn, U. Rudakou, J. Ruskey, F. Asayesh, K. Mufti, S. Laurent, D. Spiegelman, S. Fahn, C. Waters, P. Sardi, G. Rouleau, R. Alcalay, Z. Gan-Or (Montreal, QC, Canada)

    Objective: To examine whether the activity of the lysosomal enzyme glucocerebrosidase (GCase) is associated with LRRK2 variants. Background: Mutations in GBA (which encodes GCase) and…
  • MDS Virtual Congress 2020

    LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression

    T. Usnich, N. Schell, E.J Vollstedt, V. Skrahina, X. Bogdanovic, N. Koleva-Alazeh, I. Csoti, T. Förster, A. Heuer, N. Brüggemann, P. Bauer, M. Kasten, A. Rolfs, C. Klein (Luebeck, Germany)

    Objective: The international multicenter LIPAD study is a deep-phenotyping, follow-up study to ROPAD (Rostock Parkinson’s Disease Study) with the aim to systematically characterize Parkinson's disease…
  • MDS Virtual Congress 2020

    Characterizing Global Cohorts with Monogenic Parkinson’s Disease

    E.J Vollstedt, S. Schaake, M. Kasten, K. Lohmann, C. Klein (Lübeck, Germany)

    Objective: To clinically and genetically characterize a global sample of subjects with monogenic Parkinson’s disease (mPD) and unaffected mutation carriers. Background: Publications on patients with…
  • MDS Virtual Congress 2020

    The role of peripheral T- and B-lymphocytes in LRRK2-mediated Parkinson’s disease

    E. Kozina, M. Byrne, L. Oakley, R. Smeyne (Philadelphia, PA, USA)

    Objective: To test the hypothesis the neurodegenerative cascade in the CNS that leads to Parkinson’s disease (PD) is initiated by signals emanating from the peripheral…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley